It’s time to take a deep dive into the Health Tech start-up taking a stand against the Roe v Wade decision
The goal of Alife is to modernize and adapt the IVF process using the power of AI. They’ve built one of the vastest IVF data collections, made up of millions of patient cycles, taking information from some of the most respected fertility clinics around the globe. Through data analysis, Alife can calculate effective treatment plans for patients and make personalized IVF plans.
The first product they launched was called Stim Assist, which essentially assists clinicians with their decision-making during ovarian simulations with AI. The process is where the patient is injected with medications to induce the ovaries to produce mature eggs to remove them from the uterus, fertilize them and reimplant them.
They also have plans to release a product for patients later this year. The Alife mobile app hopes to provide a platform containing educational resources and accessibility for lab results, appointments, and more for the patients to have. Embryo Predict is the name of their 3rd product, an AI-based tool that can run diagnostics on patient embryos. Then embryologists can select them for transfer.
Alife Health Announces its $22 Million Funding
A single IVF cycle in the U.S. costs around $12,000, and with medication on top, they can soar to around $25,000. But on March 22, 2022, the tech start-up announced that $22 million was raised in a Series A financing co-led by existing Seed lead Deena Shakir at Lux Capital.
The data-driven patient insights and personalization to IVF clinical decisions is what Alife strives for, as well as lowering the costs and restrictions to access today. About 10 percent of women (6.1 million) in the United States ages 15-44 have difficulty getting pregnant or staying pregnant (womenshealth.gov), not even including the challenge of costly treatment.
Alife announced that it had raised $22 million in series A funding. Further advancements in distributing fertility products and research for new products will now advance more promptly.
Roe v. Wade Decision: A Letter from the CEO of Alife
“Today’s Supreme Court decision to overturn an individual’s protected right to privacy and allow state governments to impede access to medical care is deeply saddening and disheartening. Alife stands with all patients seeking support and remains resolute in our promise to help them navigate this new and challenging landscape” (Paxton Maeder-York, CEO of Alife). This letter was created on the 24th June following the recent developments and they acknowledge that the pre-existing issues of hurdles patients had to go through are only increasing. Financial restraints and effectiveness of the treatments will now be met with the requirement to travel cross-country just to access it.
They aim to keep fighting on behalf of women’s rights for successful IVF treatments and continue to develop innovative tech that will make reproductive medicine more accessible, affordable and effective. Their founder Paxton has made it clear that they stand with all the patients seeking support and the company aims to help them in the new climate.
Are you looking for help with your health tech company?
If you are looking for sourcing the best talent for your health tech company, feel free to get in touch. We can have a no-obligation chat for your business needs, so feel free to complete our contact form on our website